<DOC>
	<DOCNO>NCT01602068</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ocular iontophoresis dexamethasone phosphate ophthalmic solution EGP-437 use EyeGate® II Drug Delivery System ( EGDS ) compare placebo patient undergo cataract surgery implantation posterior chamber intraocular lens .</brief_summary>
	<brief_title>Safety Efficacy Study Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Patients Undergoing Cataract Surgery With Implantation Posterior Chamber Intraocular Lens</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Undergoing unilateral cataract extraction implantation monofocal IOL ( time enrollment ) Male female 18 year older Receive , understand , sign copy write informed consent form Be able return study visit willing comply studyrelated instruction Subjects meet inclusion criterion Subjects implant multifocal IOL Ocular surgery kind study eye within 6 month prior baseline visit Cataract surgery fellow eye within 6 week , include 2 week without topical ocular medication , prior baseline visit Scheduled surgery fellow eye within study period Have anterior chamber inflammation measure slit lamp examination baseline . Anterior chamber cell and/or flare grade &gt; 0 Have use topical ocular medication either eye , tear substitute dry eye , least 2 week prior baseline visit Have IOP ≥ 25 mmHg baseline , history glaucoma , require ocular antihypertensive medication Be know corticosteroid intraocular pressure responder either eye Have use topical corticosteroid NSAID treatment either eye ≤ 48 hour prior baseline visit Systemic administration corticosteroid within past 14 day prior baseline visit Have receive intravitreal , subTenon 's , periocular corticosteroid treatment either eye within past 6 month prior baseline visit Have open wounds/ skin disease forehead area iontophoresis return electrode apply Have severe lesion eyelid ocular surface impede application iontophoresis applicator Have blepharospasm , blepharophimosis , eyelid anatomic variation preclude placement iontophoresis applicator Have significant Fuch 's Corneal Dystrophy Have know allergy dexamethasone dexamethasone phosphate medication use study Have history diagnosis ocular herpes , corneal lesion suspect herpetic origin Have optic neuritis origin Have clinically suspect confirmed central nervous system ocular lymphoma Have active hyphema , par planitis , choroiditis , Behçet 's disease , clinically significant macular edema , toxoplasmosis scar , vitreous hemorrhage Have severe/serious ocular pathology medical condition may preclude study completion History HIV/AIDS Have pacemaker and/or electrical sensitive support system Be pregnant lactate female , female childbearing age use inadequate birth control method Have participate another investigational device drug study within 30 day baseline visit Have already participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Iontophoresis</keyword>
	<keyword>Cataract Surgery</keyword>
	<keyword>Ophthalmology</keyword>
</DOC>